KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Acadia Pharmaceuticals (ACAD) over the last 12 years, with Q3 2025 value amounting to $115.8 million.

  • Acadia Pharmaceuticals' Receivables - Net rose 1796.27% to $115.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $115.8 million, marking a year-over-year increase of 1796.27%. This contributed to the annual value of $98.7 million for FY2024, which is 48.03% up from last year.
  • Latest data reveals that Acadia Pharmaceuticals reported Receivables - Net of $115.8 million as of Q3 2025, which was up 1796.27% from $107.5 million recorded in Q2 2025.
  • Acadia Pharmaceuticals' Receivables - Net's 5-year high stood at $115.8 million during Q3 2025, with a 5-year trough of $51.4 million in Q2 2021.
  • For the 5-year period, Acadia Pharmaceuticals' Receivables - Net averaged around $81.3 million, with its median value being $81.9 million (2023).
  • In the last 5 years, Acadia Pharmaceuticals' Receivables - Net crashed by 817.68% in 2022 and then soared by 6651.18% in 2023.
  • Quarter analysis of 5 years shows Acadia Pharmaceuticals' Receivables - Net stood at $64.4 million in 2021, then decreased by 3.37% to $62.2 million in 2022, then soared by 58.0% to $98.3 million in 2023, then grew by 0.48% to $98.7 million in 2024, then rose by 17.33% to $115.8 million in 2025.
  • Its Receivables - Net stands at $115.8 million for Q3 2025, versus $107.5 million for Q2 2025 and $105.7 million for Q1 2025.